From Jim Cramer the street news today and TEVA is down #$%$
Currently there are 11 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 14 rate it a hold.
TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.